What is EndoSim?
EndoSim operates at the intersection of medical research and clinical training, providing endoscopists with sophisticated ex-vivo simulation vehicles designed to refine technical proficiency. The company distinguishes itself through a rigorous, evidence-based methodology, with its training modules and simulation products validated by peer-reviewed endoscopy journals. By addressing the critical need for repetitive, high-fidelity practice, EndoSim directly impacts clinical success rates, specifically targeting the reduction of perforation percentages during complex procedures such as ESD and EMR hemostasis. This focus on measurable outcomes establishes the firm as a vital partner for healthcare institutions aiming to elevate the standard of care through advanced procedural mastery.
How much funding has EndoSim raised?
EndoSim has raised a total of $31K across 1 funding round:
Debt
$31K
Debt (2021): $31K with participation from PPP
Key Investors in EndoSim
PPP
Public-Private Partnership
What's next for EndoSim?
With the recent influx of substantial expansion capital, EndoSim is well-positioned to accelerate its market penetration and broaden its portfolio of training courses. The strategic roadmap likely involves scaling the production of its ex-vivo specimens and expanding the reach of its specialized workshops to a global audience of medical professionals. As the healthcare sector continues to prioritize patient safety and procedural efficiency, EndoSim's commitment to research-validated training provides a robust foundation for long-term growth. Future initiatives will likely focus on integrating new procedural simulations into their curriculum, further cementing their role as a leader in the medical simulation industry and driving sustained value for both clinical partners and stakeholders.
See full EndoSim company page
